Pieris PharmaceuticalsPIRS
Market Cap: $23.1M
About: Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States.
Employees: 50
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
9.69% less ownership
Funds ownership: 38.2% [Q1] → 28.51% (-9.69%) [Q2]
49% less funds holding
Funds holding: 41 [Q1] → 21 (-20) [Q2]
51% less capital invested
Capital invested by funds: $7.25M [Q1] → $3.58M (-$3.67M) [Q2]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 20
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 20
Research analyst outlook
We haven’t received any recent analyst ratings for PIRS.